Organic Smokes

Piyush, Nitin, and Gaurav Chhabra are the co-founders of Me Ame, the parent company of Organic Smokes. Piyush is the CEO, while the other two were Managing Directors. All of them are brothers living in a joint family. They funnily call themselves THC The Herbal Chhabras a deliberate play on the cannabis abbreviation that signals their irreverent brand personality. The founders told the Sharks about their family business of Ayurvedic medicine and how they thought of experimenting with smoking organic herbs in their leisure time. The founding origin is quintessentially curious three brothers from a family with Ayurvedic medicine heritage, experimenting with herb-smoking as a personal wellness exploration, and discovering that the experience was enjoyable enough to commercialise.

The company makes organic and biodegradable cigarettes from exotic herbs and unique substances such as Tulsi, Green Tea, Rose Petals, Spearmint, etc. They replaced nicotine with caffeine to manage the placebo effect. The products of Organic Smokes are patented and approved by the Ministry of Ayush. The product targets two distinct consumer segments: Tobacco smokers seeking a nicotine-free, less harmful alternative that maintains the physical ritual of smoking Wellness-conscious consumers who see herbal smoking as an Ayurvedic therapeutic practice rather than a nicotine delivery mechanism

Amount Asked: ₹1 crore Equity Offered: 1% Implied Pre-Money Valuation: ₹100 crore

The Chhabra brothers walked into the Tank as Season 2 Episode 5's most unexpected and most entertaining pitch three real brothers from Sonipat introducing themselves as "THC, The Herbal Chhabras," the self-deprecating acronym that immediately communicated their personality: irreverent, confident, and completely comfortable with the unconventional nature of what they were selling. The product demonstration was the pitch's most viscerally unusual moment the brothers lit their herbal cigarettes inside the Shark Tank studio, allowing the Sharks to smell the herbs (Tulsi, Green Tea, Rose Petals) and contrast the experience with conventional tobacco smoke. The absence of tobacco smell in the room was the most immediate and most organic product demonstration possible.

Peyush Bansal was the most enthusiastic Shark calling the brothers "Disruptive Entrepreneurs" and engaging seriously with the Ayurvedic smoking therapy concept Namita Thapar exited on expertise grounds. Namita was out of the deal as her expertise was not aligned with the products, and she couldn't make out from the pitch what the founders were really aiming to achieve. Anupam Mittal raised the most scientifically direct concern. Anupam refuted the founders' claims that their products have no side effects, as any fume is harmful to the body. Aman Gupta enquired about how and where they are selling their products. He exited after establishing that the sales were heavily distributor-dependent and that consumer pull (organic end-consumer demand) was not yet the primary revenue driver. Amit Jain exited citing doubts about health claims and business scalability consistent with the panel's consensus that the product's wellness claims needed more clinical validation before institutional investment was appropriate.

No Shark made a formal offer. All five exited without entering negotiation. The concerns were unanimous health claim scientific basis, sales channel dependency on distributors rather than consumer demand, and scalability uncertainty in a product category requiring both consumer education and regulatory navigation. The ₹100 crore implied valuation on ₹5 crore targeted annual revenue (20x forward revenue multiple) was also considered too aggressive for an early-stage herbal product company.

Organic Smokes walked out of Shark Tank India Season 2 Episode 5 without any investment. Despite Peyush Bansal calling the founders "Disruptive Entrepreneurs," being the first herbal cigarette brand to appear on Shark Tank India, and generating instant social media enthusiasm, all five Sharks declined to invest citing concerns about the scientific basis of health claims, the distributor-heavy rather than consumer-driven revenue model, and scalability uncertainty in a novel product category.